MCM
DMII

Moore Capital Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Moore Capital Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.48M Hold
750,000
– – 0.15% 115
2025
Q4 		$7.42M Buy
+750,000
New +$7.41M 0.11% 195

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Moore Capital Management's DMII Position: Q1 2026 in Review

Moore Capital Management held its Drugs Made In America Acquisition II Corp (DMII) position steady in Q1 2026 at 750,000 shares worth $7.48M. The position accounts for 0.15% of the portfolio, ranked #115.

Moore Capital Management first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Moore Capital Management held 750,000 shares of Drugs Made In America Acquisition II Corp worth $7.48M as of Q1 2026.
  • Moore Capital Management left its Drugs Made In America Acquisition II Corp share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition II Corp made up 0.15% of Moore Capital Management's portfolio in Q1 2026, its #115 holding.
  • Moore Capital Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.